Do You Have Patients with a FEV1 <50% Predicted?
Is Medical Management No Longer Enough?
For patients with severe COPD/Emphysema in need of another option, Zephyr Valves may help improve lung function, exercise capacity, and quality of life – without traditional surgery and many of its associated risks.20
Download the Physician Guide to Review:
- Clinical evidence
- Patient selection criteria
- Treatment guidelines
- Referral criteria and how to make a referral
Complete the Form to Download the Guide
"*" indicates required fields
See Why Zephyr® Valves are the
#1 Used Endobronchial Valve to Treat Hyperinflation Associated with Severe COPD/Emphysema*
Changing the Standard of Care for Severe COPD/Emphysema Treatment:
- Included in treatment guidelines
- Gold Evidence “A” rating
- Received FDA approval in 2018
- Backed by 100 scientific studies
- >25k patients treated globally
*Supporting data on file.
Review Clinical Case Studies from Your Peers
73-year-old Male Patient
Significant improvement in FEV1, decrease in TLC and RV, and increase in 6MWD
55-year-old Female Patient
Significant improvement in RV and FEV1, decrease in TLC, and increase in 6MWD
See the Zephyr Valve Mechanism of Action
The Zephyr Endobronchial Valve is indicated for the bronchoscopic treatment of patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation (CV).
You can use this minimally invasive, implantable device to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased.
Watch this video to see how these unique one-way valves reduce gas trapping.
© 2022 Pulmonx Corporation or its affiliates. All rights reserved. All trademarks herein are the property of Pulmonx Corporation or its affiliates. US-EN-1467-v1
Privacy Policy | Terms of Use | Sitemap | Important Safety Information | In The News | Contact Us
